Dong-Anh Khuong-Quang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/624898/publications.pdf

Version: 2024-02-01

14 papers 588 citations

7 h-index 10 g-index

15 all docs 15 docs citations

15 times ranked 1419 citing authors

#	Article	IF	CITATIONS
1	<i>In vitro</i> and <i>in vivo</i> drug screens of tumor cells identify novel therapies for highâ€isk child cancer. EMBO Molecular Medicine, 2022, 14, e14608.	6.9	12
2	Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents: INFORM2 NivEnt Journal of Clinical Oncology, 2022, 40, 10034-10034.	1.6	0
3	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
4	The important role of routine cytopathology in pediatric precision oncology. Cancer Cytopathology, 2021, 129, 805-818.	2.4	4
5	Growth hormone and targeted oncological agents: Are we stopping children with brain tumours from reaching their true height potential?. Journal of Paediatrics and Child Health, 2021, 57, 1170-1174.	0.8	0
6	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nature Medicine, 2020, 26, 1742-1753.	30.7	185
7	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	28.9	93
8	Recurrent <i>SPECC1L–NTRK</i> fusions in pediatric sarcoma and brain tumors. Journal of Physical Education and Sports Management, 2020, 6, a005710.	1.2	4
9	Preoperative chemotherapy in medulloblastoma: a change in treatment paradigm?. Neuro-Oncology, 2020, 22, 1562-1563.	1.2	0
10	MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY. Neuro-Oncology, 2020, 22, iii394-iii394.	1.2	0
11	PATH-09. SJMB12 CLINICAL TRIAL: DISCREPANCY BETWEEN LOCAL AND CENTRAL PATHOLOGY IN ASSESSING ANAPLASTIC MEDULLOBLASTOMA – REPORT FROM A SINGLE SITE EXPERIENCE. Neuro-Oncology, 2020, 22, iii426-iii426.	1.2	0
12	Targeted therapy and disease monitoring in CNTRLâ€FGFR1â€driven leukaemia. Pediatric Blood and Cancer, 2019, 66, e27897.	1.5	8
13	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nature Genetics, 2018, 50, 1650-1657.	21.4	151
14	Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. British Journal of Cancer, 2018, 119, 693-696.	6.4	90